Stem cell bioprocessing for regenerative medicine

Authors

  • Tiago G. Fernandes,

    1. Department of Bioengineering and IBB - Institute for Biotechnology and Bioengineering, Instituto Superior Técnico, Technical University of Lisbon, Lisboa, Portugal
    Search for more papers by this author
    • These authors have contributed equally
  • Carlos A.V. Rodrigues,

    1. Department of Bioengineering and IBB - Institute for Biotechnology and Bioengineering, Instituto Superior Técnico, Technical University of Lisbon, Lisboa, Portugal
    Search for more papers by this author
    • These authors have contributed equally
  • Maria Margarida Diogo,

    1. Department of Bioengineering and IBB - Institute for Biotechnology and Bioengineering, Instituto Superior Técnico, Technical University of Lisbon, Lisboa, Portugal
    Search for more papers by this author
  • Joaquim M.S. Cabral

    Corresponding author
    1. Department of Bioengineering and IBB - Institute for Biotechnology and Bioengineering, Instituto Superior Técnico, Technical University of Lisbon, Lisboa, Portugal
    • Correspondence to: J.M.S. Cabral, Department of Bioengineering and IBB - Institute for Biotechnology and Bioengineering, Instituto Superior Técnico, Technical University of Lisbon, Av. Rovisco Pais, 1049-001, Lisboa, Portugal. E-mail: joaquim.cabral@ist.utl.pt

    Search for more papers by this author

Abstract

Stem cell-derived products have the potential to represent promising therapeutic approaches for the treatment of a wide range of conditions. Neurodegenerative diseases, like Parkinson's disease or Huntington's disease, neurological disorders, cardiac failure, and blood disorders, among others, may one day be treated using cellular therapies and regenerative medicine approaches based on stem cells. Furthermore, owing to the potential positive impact in healthcare systems, translation of stem cell technologies into clinical applications will bring a broad social and economic advantage worldwide. However, to fully realize this potential, advanced bioprocessing systems are needed to deliver sufficient numbers of cells in compliance with stringent regulatory landscapes and that can be used in a safe and effective manner. This review presents and summarizes recent advancements in the field of stem cell engineering, in particular novel technologies for the interrogation of stem cell fate and systems for the robust manufacturing of cells under standardized, reproducible and strictly controlled conditions. © 2013 Society of Chemical Industry

Ancillary